Cargando…

Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes

AIMS/INTRODUCTION: The efficacy and safety of drugs can vary between different races or ethnic populations because of differences in the relationship of dose to exposure, pharmacodynamic response or clinical efficacy and safety. In the present post‐hoc analysis, we assessed the influence of race on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarashina, Akiko, Friedrich, Christian, Crowe, Susanne, Patel, Sanjay, Graefe‐Mody, Ulrike, Hayashi, Naoyuki, Horie, Yoshiharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009137/ https://www.ncbi.nlm.nih.gov/pubmed/27180969 http://dx.doi.org/10.1111/jdi.12482

Ejemplares similares

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
por: Retlich, Silke, et al.
Publicado: (2015)

Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo
por: Horie, Yoshiharu, et al.
Publicado: (2009)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
por: Zimdahl, Heike, et al.
Publicado: (2014)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
por: Ceriello, Antonio, et al.
Publicado: (2016)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
por: Rauch, Thomas, et al.
Publicado: (2012)

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus
por: Kanada, Shigeto, et al.
Publicado: (2013)

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
por: Yamamoto, Fumiko, et al.
Publicado: (2020)

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
por: Yamamoto, Fumiko, et al.
Publicado: (2019)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial
por: Ma, Ronald CW, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA(®) Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants
por: Johansson, Susanne, et al.
Publicado: (2022)

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
por: Zeng, Yi-Hong, et al.
Publicado: (2022)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Linagliptin-Associated Alopecia and Bullous Pemphigoid
por: Someili, Ali, et al.
Publicado: (2019)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
por: Jadhav, Sushant B., et al.
Publicado: (2016)

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial
por: Chen, Yuhong, et al.
Publicado: (2015)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
por: Groop, P-H, et al.
Publicado: (2014)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

Clinical utility and tolerability of linagliptin in diabetic patients
por: Maxwell, Lauralee Gordon, et al.
Publicado: (2013)

Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
por: Li, Yong, et al.
Publicado: (2020)

Atypical Bullous Pemphigoid After Linagliptin Intake
por: Dbouk, Samer, et al.
Publicado: (2021)

DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice
por: Hasegawa, Yu, et al.
Publicado: (2017)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
por: Hall, Jesse, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P(1)R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects
por: Juif, Pierre‐Eric, et al.
Publicado: (2020)

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
por: Miyawaki, Yoshia, et al.
Publicado: (2018)

Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials
por: Ning, Guang, et al.
Publicado: (2017)

Linagliptin use in older individuals with type 2 diabetes
por: Pratley, Richard E
Publicado: (2014)

Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice
por: Nagai, Takuo, et al.
Publicado: (2016)

Post-marketing Study of Linagliptin: A Pilot Study
por: Gomes, Gabrielle Kéfrem Alves, et al.
Publicado: (2019)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Spectrophotometric Methods for the Determination of Linagliptin in Binary Mixture with Metformin Hydrochloride and Simultaneous Determination of Linagliptin and Metformin Hydrochloride using High Performance Liquid Chromatography
por: El-Bagary, Ramzia I., et al.
Publicado: (2013)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kms8sieh989a1hqvqisap6k6kb